Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECC chemotherapy with or without pravastatin in advanced gastric carcinoma
ISRCTN23062732Phase 2Completed
- Sponsor
- Erasmus MC
- Start
- Feb 2005
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pravastatin, epirubicin, cisplatin and capecitabine in gastric adenocarcinoma (2 arms), sponsored by Erasmus MC. Primary endpoint: Progression-free survival rate at 6 months. Started Feb 2005; status: completed.
02
Drugs
pravastatinepirubicincisplatincapecitabine
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on ISRCTN23062732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN23062732.